The risk management plan as an instrument to avoid safety risks of medicines

• In: G22 - Patient Safety, Risk Assessment and Risk Management on Wednesday, 3 September 2008, 14:00-17:00
• At: Basel (Switzerland) (2008)
• Type: Presentation
• By: GOLDAMMER, Mark (Charité, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany)
• Abstract:

  Several withdrawals of medicines like Vioxx and Lipobay in recent years emphasize the importance of ensuring the safety of medicinal products in an early stage of the development and introduction of new medicines into the market. Although the main purpose of safety measures is to protect the health of the users there is also a cost benefit issue

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login